Justin Miller
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Justin Miller has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Alex Matika
Department of Pharmacy, St. Luke’s University Health Network, Bethlehem, USA
1 shared publication - Benjamin A. Wilkinson
St. Luke's University Health Network Bethlehem Pennsylvania USA
1 shared publication Brad Hall
Department of Pharmacy, Lakeland Regional Health, Lakeland, FL, United States of America
1 shared publication- Esrat Jahan
Department of Pharmacy, St. Luke’s University Health Network, Bethlehem, USA
1 shared publication - Haley L. Kavelak
St. Luke's University Health Network Bethlehem Pennsylvania USA
1 shared publication Jessica Cobian
Department of Pharmacy, Lakeland Regional Health, Lakeland, FL, United States of America
1 shared publication
Latest Publications
- 27 August 2026
- Published by Springer Nature in Infection
- Vol. 54 (5) , 2663-2670
Oral transition therapy versus intravenous therapy for the treatment of uncomplicated Enterococcal bloodstream infections
Purpose Growing evidence supports oral transition therapy for gram-negative and certain Staphylococcus bloodstream infections (BSIs). However, clinical data remains limited for other organisms. The purpose of this study is to assess whether oral transition therapy is non-inferior to intravenous (IV)-only therapy for uncomplicated Enterococcal BSIs. Methods This single-center, retrospective, non-inferiority, observational study included adult patients with microbiology-confirmed Enterococcus bacteremia who received appropriate definitive antibiotic therapy. The primary composite outcome was treatment failure, defined as recurrence of BSI, development of deep-seated infection, or all-cause mortality within 90 days. Secondary outcomes included the individual components of the composite outcome, readmission within 90 days related to the index infection, hospital length of stay, and treatment-emergent adverse events. Results Of the 156 included patients, 123 received IV-only therapy, and 33 were transitioned to oral therapy. Treatment failure occurred in 18% (22/123) of patients in the IV-only group and 12% (4/33) in the oral group (RR 0.68, 95% CI 0.25–1.83), with a similar safety profile observed in both groups. Additionally, the hospital length of stay was significantly shorter in the oral group (6 vs. 8 days, p < 0.01). Conclusion Given this study was underpowered, a statistical non-inferiority could not be established. However, given a numerically lower rate of treatment failure observed in the oral therapy group without any overt safety concern, oral transition therapy may be considered in clinically stable patients with uncomplicated Enterococcal BSIs.
- 27 August 2026
- Published by Springer Nature in Infection
- Vol. 54 (5) , 2663-2670
Oral transition therapy versus intravenous therapy for the treatment of uncomplicated Enterococcal bloodstream infections
Purpose Growing evidence supports oral transition therapy for gram-negative and certain Staphylococcus bloodstream infections (BSIs). However, clinical data remains limited for other organisms. The purpose of this study is to assess whether oral transition therapy is non-inferior to intravenous (IV)-only therapy for uncomplicated Enterococcal BSIs. Methods This single-center, retrospective, non-inferiority, observational study included adult patients with microbiology-confirmed Enterococcus bacteremia who received appropriate definitive antibiotic therapy. The primary composite outcome was treatment failure, defined as recurrence of BSI, development of deep-seated infection, or all-cause mortality within 90 days. Secondary outcomes included the individual components of the composite outcome, readmission within 90 days related to the index infection, hospital length of stay, and treatment-emergent adverse events. Results Of the 156 included patients, 123 received IV-only therapy, and 33 were transitioned to oral therapy. Treatment failure occurred in 18% (22/123) of patients in the IV-only group and 12% (4/33) in the oral group (RR 0.68, 95% CI 0.25–1.83), with a similar safety profile observed in both groups. Additionally, the hospital length of stay was significantly shorter in the oral group (6 vs. 8 days, p < 0.01). Conclusion Given this study was underpowered, a statistical non-inferiority could not be established. However, given a numerically lower rate of treatment failure observed in the oral therapy group without any overt safety concern, oral transition therapy may be considered in clinically stable patients with uncomplicated Enterococcal BSIs.
- 25 November 2025
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 45 (12) , 809-814
Intravenous Push Levetiracetam Administration Compared With Intravenous Piggyback on Benzodiazepine Use for Acute Seizure Treatment
Introduction: Levetiracetam (LEV) is indicated for benzodiazepine (BZD) refractory status epilepticus (SE) and is traditionally administered as an intravenous piggyback (IVPB) infused over 15 min, although rapid intravenous push (IVP) administration over 2 to 5 min has gained popularity. Current literature surrounding IVP LEV administration supports increased efficiency and equal safety of IVP compared with IVPB, though efficacy comparisons, such as seizure duration, are limited. The objective of this study was to assess the impact of IVP LEV on seizure duration and BZD requirements. Methods: This retrospective cohort study assessed adult patients who received IVP or IVPB LEV following a BZD for an acute or suspected seizure. The primary outcome was the number of patients who required additional BZD doses between LEV order and administration. Secondary outcomes included additional BZD requirement within 6 h after LEV administration, time from LEV order to administration, need for intubation, and intensive care unit (ICU) admission. Safety outcomes assessed included bradycardia, hypotension, and infusion site reactions. Results: A total of 299 patients were included, 144 in the IVP group and 155 in the IVPB group. Fewer patients required additional BZD doses between LEV order and administration in the IVP group than the IVPB group (8 patients [5.6%] vs. 27 patients [17.4%]; p = 0.002). Additionally, the median time from LEV order to administration was shorter in the IVP group than in the IVPB group (14.5 min vs. 29.0 min; p < 0.001). Bradycardia occurred more frequently in the IVPB group compared with the IVP group (8.8% vs. 2.3%; p = 0.03). Conclusion: IVP LEV was associated with less frequent requirement of additional BZD doses for treatment of acute or suspected seizures compared with IVPB, as well as a faster time to medication administration and potentially a lower risk of bradycardia.
- 25 November 2025
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 45 (12) , 809-814
Intravenous Push Levetiracetam Administration Compared With Intravenous Piggyback on Benzodiazepine Use for Acute Seizure Treatment
Introduction: Levetiracetam (LEV) is indicated for benzodiazepine (BZD) refractory status epilepticus (SE) and is traditionally administered as an intravenous piggyback (IVPB) infused over 15 min, although rapid intravenous push (IVP) administration over 2 to 5 min has gained popularity. Current literature surrounding IVP LEV administration supports increased efficiency and equal safety of IVP compared with IVPB, though efficacy comparisons, such as seizure duration, are limited. The objective of this study was to assess the impact of IVP LEV on seizure duration and BZD requirements. Methods: This retrospective cohort study assessed adult patients who received IVP or IVPB LEV following a BZD for an acute or suspected seizure. The primary outcome was the number of patients who required additional BZD doses between LEV order and administration. Secondary outcomes included additional BZD requirement within 6 h after LEV administration, time from LEV order to administration, need for intubation, and intensive care unit (ICU) admission. Safety outcomes assessed included bradycardia, hypotension, and infusion site reactions. Results: A total of 299 patients were included, 144 in the IVP group and 155 in the IVPB group. Fewer patients required additional BZD doses between LEV order and administration in the IVP group than the IVPB group (8 patients [5.6%] vs. 27 patients [17.4%]; p = 0.002). Additionally, the median time from LEV order to administration was shorter in the IVP group than in the IVPB group (14.5 min vs. 29.0 min; p < 0.001). Bradycardia occurred more frequently in the IVPB group compared with the IVP group (8.8% vs. 2.3%; p = 0.03). Conclusion: IVP LEV was associated with less frequent requirement of additional BZD doses for treatment of acute or suspected seizures compared with IVPB, as well as a faster time to medication administration and potentially a lower risk of bradycardia.
- 1 December 2020
- Published by Elsevier in The American Journal of Emergency Medicine
- Vol. 38 (12) , 2570-2573
Impact of SEP-1 on broad-spectrum combination antibiotic therapy in the emergency department
- 1 December 2020
- Published by Elsevier in The American Journal of Emergency Medicine
- Vol. 38 (12) , 2570-2573
Impact of SEP-1 on broad-spectrum combination antibiotic therapy in the emergency department